Key result
c-Jun N-terminal kinase (JNK) was identified as a prominently activated molecule in human abdominal aortic aneurysm samples, leading to enhanced matrix metalloproteinase activity.
Answers are grounded in this paper and cite their sources.
JNK merits exploration as an AAA therapeutic target; hypothesis-generating from level 5 tissue data and requires prospective validation.
Despite the advances in molecular cell biology, identification of a therapeutic target in a given disease still poses a significant challenge. Here we report a strategy for identification of the therapeutic target in abdominal aortic aneurysm (AAA). We screened for various signaling molecules in human AAA samples and identified c-Jun N-terminal kinase (JNK) as a prominently activated molecule. The JNK pathway-oriented transcriptome analyses revealed that activation of JNK leads to enhancement of the activity of matrix metalloproteinases and, concurrently, suppression of the extracellular matrix biosynthesis, suggesting that JNK may represent a novel therapeutic target in AAA.
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2006) studied Abdominal aortic aneurysm (AAA). c-Jun N-terminal kinase (JNK) was evaluated on JNK activation and downstream effects on matrix metalloproteinases and extracellular matrix biosynthesis. c-Jun N-terminal kinase (JNK) was identified as a prominently activated molecule in human abdominal aortic aneurysm samples, leading to enhanced matrix metalloproteinase activity.
Synapse has enriched 10 related papers. Consider them for comparative context: